Literature DB >> 8799242

Assessment of myocardial viability with two-dimensional echocardiography and magnetic resonance imaging.

J R Lindner1, S Kaul.   

Abstract

In a patient with coronary artery disease, clinical, electrocardiographic, and angiographic information is often inadequate for determining the presence of viable tissue. The presence of wall thickening, even if reduced, indicates that the myocardium is viable. When wall thickening is absent, the myocardium may or may not be viable. The basis for the underlying myocardial dysfunction may be multifactorial in a single patient or even in a single myocardial segment. Cardiac imaging techniques are most useful in defining the mechanisms of underlying myocardial dysfunction and assist in selecting the optimal management strategy for patients. This review discusses the role of two-dimensional echocardiography and magnetic resonance imaging for the assessment of myocardial viability.

Entities:  

Mesh:

Year:  1996        PMID: 8799242     DOI: 10.1016/s1071-3581(96)90009-4

Source DB:  PubMed          Journal:  J Nucl Cardiol        ISSN: 1071-3581            Impact factor:   5.952


  85 in total

1.  Cine MR determination of left ventricular ejection fraction.

Authors:  J A Utz; R J Herfkens; J A Heinsimer; T Bashore; R Califf; G Glover; N Pelc; A Shimakawa
Journal:  AJR Am J Roentgenol       Date:  1987-05       Impact factor: 3.959

2.  Two-dimensional echocardiography and infarct size: relationship of regional wall motion and thickening to the extent of myocardial infarction in the dog.

Authors:  A N Lieberman; J L Weiss; B I Jugdutt; L C Becker; B H Bulkley; J G Garrison; G M Hutchins; C A Kallman; M L Weisfeldt
Journal:  Circulation       Date:  1981-04       Impact factor: 29.690

Review 3.  Echocardiography in coronary artery disease.

Authors:  S Kaul
Journal:  Curr Probl Cardiol       Date:  1990-05       Impact factor: 5.200

4.  Beta-adrenergic stimulation reverses postischemic myocardial dysfunction without producing subsequent functional deterioration.

Authors:  R Bolli; W X Zhu; M L Myers; C J Hartley; R Roberts
Journal:  Am J Cardiol       Date:  1985-12-01       Impact factor: 2.778

5.  Detection of viable myocardium in segments with fixed defects on thallium-201 scintigraphy: usefulness of magnetic resonance imaging early after acute myocardial infarction.

Authors:  D L Johnston; V K Gupta; R E Wendt; J J Mahmarian; M S Verani
Journal:  Magn Reson Imaging       Date:  1993       Impact factor: 2.546

6.  On-line intraoperative quantitation of regional myocardial perfusion during coronary artery bypass graft operations with myocardial contrast two-dimensional echocardiography.

Authors:  F S Villanueva; W D Spotnitz; A R Jayaweera; J Dent; L W Gimple; S Kaul
Journal:  J Thorac Cardiovasc Surg       Date:  1992-12       Impact factor: 5.209

7.  Infarct expansion: pathologic analysis of 204 patients with a single myocardial infarct.

Authors:  J S Pirolo; G M Hutchins; G W Moore
Journal:  J Am Coll Cardiol       Date:  1986-02       Impact factor: 24.094

8.  Regional redistribution of myocardial blood flow after coronary occlusion and reperfusion in the conscious dog.

Authors:  F C White; M Sanders; C M Bloor
Journal:  Am J Cardiol       Date:  1978-08       Impact factor: 2.778

9.  The "no-reflow" phenomenon after temporary coronary occlusion in the dog.

Authors:  R A Kloner; C E Ganote; R B Jennings
Journal:  J Clin Invest       Date:  1974-12       Impact factor: 14.808

10.  Dobutamine echocardiography predicts improvement of hypoperfused dysfunctional myocardium after revascularization in patients with coronary artery disease.

Authors:  P Perrone-Filardi; L Pace; M Prastaro; F Piscione; S Betocchi; F Squame; P Vezzuto; A Soricelli; C Indolfi; M Salvatore
Journal:  Circulation       Date:  1995-05-15       Impact factor: 29.690

View more
  1 in total

1.  Functional cardiac magnetic resonance imaging (MRI) in the assessment of myocardial viability and perfusion: an evidence-based analysis.

Authors: 
Journal:  Ont Health Technol Assess Ser       Date:  2003-11-01
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.